G Mason Morfit Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for G Mason Morfit.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of G Mason Morfit. G Mason Morfit is Director in BARD C R INC /NJ/ ($BCR) and Director in VALEANT PHARMACEUTICALS INTERNATIONAL ($ICN) and Director in IMMUCOR INC ($BLUD) and Director in Solexa, Inc. ($LYNX) and Director in MICROSOFT CORP ($MSFT) and Director in Valeant Pharmaceuticals International, Inc. ($BVF) and in ABBOTT MEDICAL OPTICS INC ($AVO) and Director in ABBOTT MEDICAL OPTICS INC ($AVO).
Latest Insider Trading Transactions of G Mason Morfit
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVO, BCR, BVF, BLUD, MSFT, LYNX, ICN
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 30 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 589 | 0 | 589 | 0 to 589 |
Aug 31 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 675 | 0 | 675 | 0 to 675 |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.50 | 30,169 | 2,187,253 | 881,949 | 912.1 K to 881.9 K (-3.31 %) |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.50 | 278,000 | 20,155,000 | 8,130,850 | 8.4 M to 8.1 M (-3.31 %) |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.50 | 312,331 | 22,643,998 | 912,118 | 1.2 M to 912.1 K (-25.51 %) |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.50 | 2,879,500 | 208,763,750 | 8,408,850 | 11.3 M to 8.4 M (-25.51 %) |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.61 | 342,600 | 24,876,186 | 1,224,449 | 1.6 M to 1.2 M (-21.86 %) |
Aug 08 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 72.61 | 3,157,400 | 229,258,814 | 11,288,350 | 14.4 M to 11.3 M (-21.86 %) |
May 31 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 710 | 0 | 710 | 0 to 710 |
May 05 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 68.82 | 391,500 | 26,943,030 | 1,567,049 | 2 M to 1.6 M (-19.99 %) |
May 05 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 68.82 | 3,608,500 | 248,336,970 | 14,445,040 | 18.1 M to 14.4 M (-19.99 %) |
May 05 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 68.89 | 293,600 | 20,226,104 | 1,958,549 | 2.3 M to 2 M (-13.04 %) |
May 05 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 68.89 | 2,706,400 | 186,443,896 | 18,053,540 | 20.8 M to 18.1 M (-13.04 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.33 | 195,700 | 12,393,681 | 2,703,849 | 2.9 M to 2.7 M (-6.75 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.33 | 1,804,300 | 114,266,319 | 24,922,648 | 26.7 M to 24.9 M (-6.75 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.12 | 587,200 | 37,064,064 | 2,899,549 | 3.5 M to 2.9 M (-16.84 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.12 | 5,412,800 | 341,655,936 | 26,726,948 | 32.1 M to 26.7 M (-16.84 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.72 | 293,600 | 18,708,192 | 3,486,749 | 3.8 M to 3.5 M (-7.77 %) |
Feb 03 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 63.72 | 2,706,400 | 172,451,808 | 32,139,748 | 34.8 M to 32.1 M (-7.77 %) |
Feb 01 2017 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 773 | 0 | 1,592 | 819 to 1.6 K (+94.38 %) |
Dec 01 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 819 | 0 | 819 | 0 to 819 |
Sep 06 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 867 | 0 | 1,819 | 952 to 1.8 K (+91.07 %) |
Jul 29 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 55.95 | 1,078,000 | 60,314,100 | 3,780,349 | 4.9 M to 3.8 M (-22.19 %) |
Jul 29 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 55.95 | 9,922,000 | 555,135,900 | 34,844,329 | 44.8 M to 34.8 M (-22.16 %) |
Jul 29 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 56.38 | 686,000 | 38,676,680 | 4,858,349 | 5.5 M to 4.9 M (-12.37 %) |
Jul 29 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 56.38 | 6,314,000 | 355,983,320 | 44,766,329 | 51.1 M to 44.8 M (-12.36 %) |
Jun 03 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 952 | 0 | 952 | 0 to 952 |
May 09 2016 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 1,883 | 0 | 1,883 | 0 to 1.9 K |
Feb 01 2016 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 908 | 0 | 908 | 0 to 908 |
Dec 03 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 679 | 0 | 679 | 0 to 679 |
Nov 12 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 53.74 | 259,480 | 13,944,455 | 5,544,349 | 5.8 M to 5.5 M (-4.47 %) |
Nov 12 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 53.74 | 2,390,520 | 128,466,545 | 51,078,742 | 53.5 M to 51.1 M (-4.47 %) |
Nov 12 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 53.49 | 1,566,672 | 83,801,285 | 5,803,829 | 7.4 M to 5.8 M (-21.26 %) |
Nov 12 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Sell | S | 53.49 | 14,433,328 | 772,038,715 | 53,469,262 | 67.9 M to 53.5 M (-21.26 %) |
Sep 04 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 862 | 0 | 862 | 0 to 862 |
Jun 04 2015 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Grant | A | 0.00 | 800 | 0 | 800 | 0 to 800 |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.59 | 500,000 | 19,795,000 | 7,370,501 | 6.9 M to 7.4 M (+7.28 %) |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.58 | 600,000 | 23,748,000 | 6,870,501 | 6.3 M to 6.9 M (+9.57 %) |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.56 | 800,000 | 31,648,000 | 6,270,501 | 5.5 M to 6.3 M (+14.62 %) |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.54 | 463,000 | 18,307,020 | 5,470,501 | 5 M to 5.5 M (+9.25 %) |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.50 | 287,501 | 11,356,290 | 5,007,501 | 4.7 M to 5 M (+6.09 %) |
May 12 2014 | MSFT | MICROSOFT CORP | Morfit G Mason | Director | Buy | P | 39.49 | 300,000 | 11,847,000 | 4,720,000 | 4.4 M to 4.7 M (+6.79 %) |
Jun 21 2013 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Buy | P | 85.00 | 1,352,941 | 114,999,985 | 1,352,941 | 0 to 1.4 M |
Jun 06 2013 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Payment of Exercise | F | 88.21 | 1,360 | 119,966 | 16,656 | 18 K to 16.7 K (-7.55 %) |
Jun 03 2013 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Option Exercise | D | 0.00 | 1,319 | 0 | 0 | |
Jun 03 2013 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Sell | D | 90.81 | 68,112 | 6,185,251 | 18,016 | 86.1 K to 18 K (-79.08 %) |
May 29 2013 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 5,022 | 0 | 86,128 | 81.1 K to 86.1 K (+6.19 %) |
Apr 19 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.14 | 10,973 | 1,109,809 | 2,861,380 | 2.9 M to 2.9 M (-0.38 %) |
Apr 11 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 103.02 | 100,000 | 10,302,000 | 3,172,353 | 3.3 M to 3.2 M (-3.06 %) |
Apr 11 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 102.87 | 100,000 | 10,287,000 | 3,272,353 | 3.4 M to 3.3 M (-2.97 %) |
Apr 11 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.53 | 100,000 | 10,153,000 | 3,372,353 | 3.5 M to 3.4 M (-2.88 %) |
Apr 16 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.68 | 100,000 | 10,168,000 | 2,872,353 | 3 M to 2.9 M (-3.36 %) |
Apr 16 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 102.51 | 100,000 | 10,251,000 | 2,972,353 | 3.1 M to 3 M (-3.25 %) |
Apr 16 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 103.01 | 100,000 | 10,301,000 | 3,072,353 | 3.2 M to 3.1 M (-3.15 %) |
Apr 04 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.13 | 100,000 | 10,113,000 | 3,472,353 | 3.6 M to 3.5 M (-2.80 %) |
Apr 04 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.05 | 32,749 | 3,309,286 | 3,572,353 | 3.6 M to 3.6 M (-0.91 %) |
Apr 04 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.03 | 11,206 | 1,132,142 | 3,605,102 | 3.6 M to 3.6 M (-0.31 %) |
Apr 01 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.01 | 8,148 | 823,029 | 3,616,308 | 3.6 M to 3.6 M (-0.22 %) |
Mar 25 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.00 | 1,700 | 171,700 | 3,624,456 | 3.6 M to 3.6 M (-0.05 %) |
Mar 20 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.12 | 14,782 | 1,494,756 | 3,626,156 | 3.6 M to 3.6 M (-0.41 %) |
Mar 20 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.33 | 61,290 | 6,210,516 | 3,640,938 | 3.7 M to 3.6 M (-1.66 %) |
Mar 20 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.32 | 100,000 | 10,132,000 | 3,702,228 | 3.8 M to 3.7 M (-2.63 %) |
Mar 15 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.64 | 100,000 | 10,164,000 | 3,802,228 | 3.9 M to 3.8 M (-2.56 %) |
Mar 15 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.51 | 100,000 | 10,151,000 | 3,902,228 | 4 M to 3.9 M (-2.50 %) |
Mar 15 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.14 | 100,000 | 10,114,000 | 4,002,228 | 4.1 M to 4 M (-2.44 %) |
Mar 12 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.11 | 100,000 | 10,111,000 | 4,102,228 | 4.2 M to 4.1 M (-2.38 %) |
Mar 12 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.01 | 695 | 70,202 | 4,202,228 | 4.2 M to 4.2 M (-0.02 %) |
Mar 12 2013 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 101.17 | 77,671 | 7,857,975 | 4,202,923 | 4.3 M to 4.2 M (-1.81 %) |
Dec 14 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Option Exercise | A | 0.00 | 715 | 0 | 715 | |
Dec 14 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Grant | A | 0.00 | 584 | 0 | 984 | 400 to 984 (+146.00 %) |
Oct 03 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.25 | 81,543 | 8,582,401 | 4,280,594 | 4.4 M to 4.3 M (-1.87 %) |
Oct 03 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.06 | 100,000 | 10,506,000 | 4,362,137 | 4.5 M to 4.4 M (-2.24 %) |
Oct 03 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Grant | A | 0.00 | 400 | 0 | 400 | 0 to 400 |
Oct 01 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.08 | 100,000 | 10,508,000 | 4,462,137 | 4.6 M to 4.5 M (-2.19 %) |
Oct 01 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.00 | 10,161 | 1,066,905 | 4,562,137 | 4.6 M to 4.6 M (-0.22 %) |
Sep 26 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.02 | 15,929 | 1,672,864 | 4,572,298 | 4.6 M to 4.6 M (-0.35 %) |
Sep 26 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.37 | 92,367 | 9,732,711 | 4,588,227 | 4.7 M to 4.6 M (-1.97 %) |
Sep 26 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 105.34 | 100,000 | 10,534,000 | 4,680,594 | 4.8 M to 4.7 M (-2.09 %) |
Aug 03 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 95.50 | 750,000 | 71,625,000 | 4,780,594 | 5.5 M to 4.8 M (-13.56 %) |
Aug 03 2012 | BCR | BARD C R INC /NJ/ | Morfit G Mason | Director | Sell | S | 98.00 | 605 | 59,290 | 5,530,594 | 5.5 M to 5.5 M (-0.01 %) |
Jun 06 2012 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 8,062 | 0 | 81,106 | 73 K to 81.1 K (+11.04 %) |
Aug 24 2011 | BLUD | IMMUCOR INC | Morfit G Mason | Director | Option Exercise | U | 19.30 | 21,200 | 409,160 | 0 | |
Aug 24 2011 | BLUD | IMMUCOR INC | Morfit G Mason | Director | Option Exercise | U | 0.00 | 5,542 | 0 | 0 | |
May 23 2011 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 4,397 | 0 | 73,044 | 68.6 K to 73 K (+6.41 %) |
Jun 14 2011 | BLUD | IMMUCOR INC | Morfit G Mason | Director | Option Exercise | A | 0.00 | 5,542 | 0 | 5,542 | |
Mar 08 2011 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 1,319 | 0 | 1,319 | |
Dec 27 2010 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 728 | 0 | 22,430 | |
Dec 27 2010 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 723 | 0 | 22,285 | |
Dec 27 2010 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 614 | 0 | 18,928 | |
Sep 30 2010 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 4,767 | 0 | 4,767 | 0 to 4.8 K |
Sep 30 2010 | BVF | Valeant Pharmaceut ... | Morfit G Mason | Director | Grant | A | 0.00 | 61,578 | 0 | 61,578 | 0 to 61.6 K |
Sep 30 2010 | ICN | VALEANT PHARMACEUT ... | Morfit G Mason | Director | Buy | D | 0.00 | 24,687 | 0 | 0 | -24,687 to 0 (-100.00 %) |
Jul 27 2010 | BLUD | IMMUCOR INC | Morfit G Mason | Director | Option Exercise | A | 19.30 | 8,031 | 154,998 | 8,031 | |
May 13 2010 | ICN | VALEANT PHARMACEUT ... | Morfit G Mason | Director | Grant | A | 0.00 | 2,677 | 0 | 24,687 | 22 K to 24.7 K (+12.16 %) |
May 14 2009 | ICN | VALEANT PHARMACEUT ... | Morfit G Mason | Director | Grant | A | 0.00 | 6,546 | 0 | 22,010 | 15.5 K to 22 K (+42.33 %) |
Feb 27 2009 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Sell | D | 22.00 | 6,235 | 137,170 | 0 | 6.2 K to 0 (-100.00 %) | |
Feb 27 2009 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Grant | A | 0.00 | 6,235 | 0 | 6,235 | 0 to 6.2 K | |
Feb 27 2009 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Sell | D | 22.00 | 6,740 | 148,280 | 0 | 6.7 K to 0 (-100.00 %) | |
Feb 27 2009 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Grant | A | 0.00 | 6,740 | 0 | 6,740 | 0 to 6.7 K | |
May 22 2008 | ICN | VALEANT PHARMACEUT ... | Morfit G Mason | Director | Grant | A | 0.00 | 7,757 | 0 | 15,464 | 7.7 K to 15.5 K (+100.65 %) |
Jun 02 2008 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 6,740 | 0 | 12,975 | |
Dec 06 2007 | AVO | ABBOTT MEDICAL OPT ... | Morfit G Mason | Director | Option Exercise | A | 0.00 | 6,235 | 0 | 6,235 | |
May 24 2007 | ICN | VALEANT PHARMACEUT ... | Morfit G Mason | Director | Grant | A | 15.57 | 7,707 | 119,998 | 7,707 | 0 to 7.7 K |
Jan 30 2007 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Option Exercise | D | 9.06 | 10,000 | 90,600 | 0 | |
Jan 30 2007 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Option Exercise | D | 5.97 | 20,000 | 119,400 | 0 | |
Jan 30 2007 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Sell | D | 0.00 | 2,890 | 0 | 0 | 2.9 K to 0 (-100.00 %) |
Oct 06 2006 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Option Exercise | A | 9.06 | 10,000 | 90,600 | 30,000 | |
Jan 18 2006 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Grant | A | 10.74 | 2,890 | 31,039 | 2,890 | 0 to 2.9 K |
Sep 08 2005 | LYNX | Solexa, Inc. | Morfit G Mason | Director | Option Exercise | A | 5.97 | 20,000 | 119,400 | 20,000 |
Page: 1